Sandoz has achieved a significant regulatory milestone with the Sandoz Owozy Semaglutide Brazil Approval after Brazil’s health authority, Agência Nacional de Vigilância Sanitária (ANVISA), granted marketing authorization for Owozy® (semaglutide). Through a strategic collaboration with Adalvo, Sandoz aims to improve access to affordable, high-quality diabetes treatment for patients across Brazil.
Quick Summary
Sandoz has received ANVISA approval for Owozy® (semaglutide) in Brazil. The medicine will be marketed in partnership with Adalvo to expand access to GLP-1 therapy for Type 2 diabetes. This approval strengthens patient access, supports affordable healthcare, and enhances competition in Brazil’s diabetes treatment market.
Overview
| Particular | Details |
|---|---|
| Company | Sandoz |
| Product | Owozy® (Semaglutide) |
| Regulatory Authority | ANVISA (Brazil) |
| Country | Brazil |
| Partner | Adalvo |
| Therapeutic Area | Type 2 Diabetes |
| Drug Class | GLP-1 Receptor Agonist |
| Approval Status | Marketing Authorization Granted |
| Published | July 2026 |
What is Owozy® (Semaglutide)?
Owozy® contains semaglutide, a GLP-1 receptor agonist used to improve blood sugar control in adults with Type 2 diabetes.
The medicine works by:
- Stimulating insulin secretion when blood glucose levels are high.
- Reducing glucagon release.
- Slowing gastric emptying.
- Promoting a feeling of fullness.
- Supporting weight management in eligible patients.
ANVISA Approves Owozy® in Brazil
Brazil’s national health regulator ANVISA has granted marketing authorization for Owozy® (semaglutide).
This approval enables Sandoz to introduce the medicine into one of Latin America’s largest pharmaceutical markets, reinforcing the company’s commitment to improving access to affordable diabetes care.
Strategic Partnership Between Sandoz and Adalvo
Sandoz will commercialize Owozy® through a strategic partnership with Adalvo, a global pharmaceutical company specializing in product development and commercialization.
The collaboration combines:
- Sandoz’s strong commercial presence.
- Adalvo’s pharmaceutical development expertise.
- Shared commitment to accessible healthcare.
- Expansion of innovative treatment options.
Why This Approval Matters
The approval is expected to deliver several important benefits:
- Greater patient access to semaglutide therapy.
- More treatment choices for Type 2 diabetes.
- Improved affordability.
- Increased competition in the GLP-1 market.
- Better long-term disease management.
About Semaglutide
Semaglutide belongs to the GLP-1 receptor agonist class of medicines.
Approved Uses
- Improve glycemic control in adults with Type 2 diabetes.
- Reduce cardiovascular risk in eligible patients.
- Support weight management according to approved indications.
Mechanism of Action
Semaglutide mimics the body’s natural GLP-1 hormone, helping regulate:
- Blood glucose levels.
- Appetite.
- Gastric emptying.
- Insulin secretion.
Benefits of Owozy®
| Benefit | Description |
|---|---|
| Better Blood Sugar Control | Helps lower blood glucose levels |
| Weight Management | Promotes satiety and appetite control |
| Cardiovascular Benefits | May reduce cardiovascular risk in eligible patients |
| Affordable Access | Expands availability of semaglutide therapy |
| Patient Convenience | Supports long-term diabetes management |
Sandoz’s Global Expansion Strategy
Sandoz continues to strengthen its global presence by expanding access to affordable generic and biosimilar medicines.
The approval of Owozy® demonstrates the company’s focus on:
- Affordable healthcare.
- Global patient access.
- Innovation in diabetes treatment.
- Sustainable healthcare systems.
- Expanding international pharmaceutical markets.
Why This News Matters for Pharmacy Students & Professionals
This approval is important because it highlights:
- Growing opportunities in regulatory affairs.
- Global drug approval pathways.
- Pharmaceutical marketing strategies.
- Biosimilar and generic medicine expansion.
- International pharmaceutical regulations.
- Future career opportunities in multinational pharmaceutical companies.
Key Highlights
| Feature | Details |
|---|---|
| Product | Owozy® |
| Generic Name | Semaglutide |
| Company | Sandoz |
| Partner | Adalvo |
| Approved By | ANVISA |
| Market | Brazil |
| Indication | Type 2 Diabetes |
| Drug Class | GLP-1 Receptor Agonist |
Important Links
| Description | Details |
|---|---|
| Official Website | Sandoz Official Website |
| Regulatory Authority | ANVISA Official Website |
| Product Update | Official Sandoz News Release |
Conclusion
The Sandoz Owozy Semaglutide Brazil Approval represents an important milestone in expanding access to diabetes care in Brazil. Through its partnership with Adalvo, Sandoz is expected to make affordable semaglutide therapy available to more patients while strengthening competition in the GLP-1 receptor agonist market. This development also reflects the growing importance of regulatory approvals in improving healthcare accessibility worldwide.
Frequently Asked Questions (FAQs)
Q1. What is Owozy®?
Owozy® is a brand of semaglutide, a GLP-1 receptor agonist used for the treatment of Type 2 diabetes.
Q2. Which authority approved Owozy® in Brazil?
The medicine received marketing authorization from ANVISA (Agência Nacional de Vigilância Sanitária).
Q3. Who will commercialize Owozy® in Brazil?
Sandoz will commercialize Owozy® in partnership with Adalvo.
Q4. What is semaglutide used for?
Semaglutide is used to improve blood sugar control, support weight management in eligible patients, and reduce cardiovascular risk in certain individuals with Type 2 diabetes.
Q5. Why is this approval important?
It expands patient access to affordable diabetes treatment and strengthens competition in Brazil’s GLP-1 medicine market.
Q6. What type of medicine is semaglutide?
Semaglutide belongs to the GLP-1 receptor agonist class.
Q7. Is Owozy® approved for weight management?
The medicine may support weight management according to its approved indications and local regulatory approval.
Q8. What does this approval mean for the pharmaceutical industry?
It reflects continued growth in global diabetes therapies, regulatory advancements, and increased availability of affordable medicines.
Recommended Products
